Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Benzodioxoles
Female
Humans
Interleukin-2
Male
Melanoma
Middle Aged
Neoplasm Metastasis
Protein Kinase Inhibitors
Quinazolines
src-Family Kinases
T-Lymphocytes
Treatment Outcome
authors with profiles
Theodore Karrison
Thomas F. Gajewski